Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 145

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Lung neoplasm malignant

Not yet recruiting

Study of osimertinib and febuxostat to improve drug delivery in patients with EGFR-mutated non-small cell lung cancer without brain metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Febuxostat
  • Sponsor:Academisch Ziekenhuis Maastricht

Malignant melanoma stage IV+1

Not yet recruiting

A study of ipilimumab and nivolumab to observe immune system changes in patients with unresectable stage III or IV melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Amsterdam UMC Stichting

Neoplasm

Not yet recruiting

A study to compare using a half dose of iomeprol versus a standard dose of iomeprol for imaging lung tumors with spectral CT scans.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Iomeprol
  • Sponsor:Fundacion De La Comunitat Valenciana Para La Gestion Del Instituto De Investigacion Sanitaria Y Biomedica De Alicante

Hepatocellular carcinoma

Not yet recruiting

A study to evaluate the safety and effectiveness of AZD9793 in adults with advanced or metastatic liver cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Colorectal cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of oxaliplatin delivered directly to the liver for patients with colorectal cancer and liver metastasis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:UZ Leuven

Squamous cell carcinoma of head and neck+1

Not yet recruiting

A study to evaluate the safety and effectiveness of PTT-4256 and nivolumab in patients with solid tumors.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Pathios Therapeutics Limited

Breast cancer

Not yet recruiting

A study to evaluate if silymarin prevents liver damage caused by ribociclib in patients with hormone receptor positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:Fondazione Oncotech Impresa Sociale

Neuroendocrine carcinoma metastatic

Not yet recruiting

A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Hospices Civils De Lyon

Haemophagocytic lymphohistiocytosis

Not yet recruiting

Comparing the timing of etoposide and dexamethasone treatment for patients with severe sporadic hemophagocytic lymphohistiocytosis in intensive care.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Etoposide
  • Sponsor:Assistance Publique Hopitaux De Paris

Endometrial cancer+7

Not yet recruiting

A study to evaluate the safety of SGN-ALPV in patients with advanced solid tumors

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:SGN-ALPV
  • Sponsor:Seagen Inc.

Glioblastoma

Not yet recruiting

Phase 3 Randomized Study of Niraparib Tosilate Monohydrate vs. Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Neurotrials LLC

Pancreatic carcinoma metastatic+1

Not yet recruiting

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.